Health Care · Surgical & Medical Instruments & Apparatus

IRTC iRhythm Holdings, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1388658136 filings
Russell 2000

IRTC at a glance

iRhythm Holdings, Inc. (IRTC, SEC CIK 1388658) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 17, 2026 and Form 4 insider filings as recently as November 19, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), iRhythm Holdings, Inc. (IRTC) reported revenue of $747.1 million (up 26.2% from FY2024) and a net loss of $44.6 million. Diluted EPS was -$1.39.
  • As of September 30, 2026, 28 institutional investment managers tracked by SignalX reported holding iRhythm Holdings, Inc. (IRTC) shares worth $1.3 billion in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by TALWALKAR ABHIJIT Y on November 19, 2026 of 7,900 shares at $96.67 per share.
  • In the last 90 days, IRTC insiders reported 1 open-market purchase ($764K) and 1 open-market sale ($94K) on Form 4, a net purchase of $670K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$747.1M
+26.2% vs prior year
Insiders · 90 days
1 buy · 1 sell
Net +$670K
13F holders
28 funds
$1.3B · −1 vs prior quarter
Latest 8-K
Nov 17, 2026
Item 7.01 · Item 8.01

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Risk Factors

  • No geopolitical or macroeconomic threat with concrete exposure detailed
  • Operational risk: dependency on Nasdaq Global Select Market listing under symbol "IRTC" for liquidity and capital access
  • Competitive risk: no named competitor or technology disruption identified in provided text
  • Financial risk: no dividends declared, retaining all funds to finance growth, no issuer repurchases

Business Overview

  • Core business model: Design, development, and commercialization of long-term continuous ambulatory cardiac monitoring (ACM) services using patch-based ECG biosensors with proprietary AI analytics
  • New product emphasis: Introduction of smaller, lighter Zio monitor System with Bluetooth and breathable adhesive, enhancing patient compliance and data quality vs prior Zio XT
  • Strategic shift: Expanding ACM adoption beyond cardiology into primary care and integrated delivery networks to capture earlier-stage patient populations with undiagnosed arrhythmias
  • Quantitative highlights: ~2,400 employees as of Dec 31, 2025; ~40% penetration of core U.S. ambulatory cardiac monitoring market; over 12 million patient reports generated
  • Noteworthy fact: Clinical studies (CAMELOT and AVALON) covering >700,000 diagnostic-naive patients demonstrate Zio LTCM Service’s highest diagnostic yield and lower costly hospitalizations than competitors

Management Discussion & Analysis

  • Revenue $747.1M, up 26% YoY from $591.8M driven by volume increases and new Zio AT customer growth
  • Operating margin -8% in 2025 vs -20% in 2024, loss from operations improved by $58.1M to ($57.4M)
  • Best performing segment: iRhythm Services volume growth with significant Zio AT revenue increase; no specific segment dollar detailed for worst performance
  • Cash flow from operations $80.9M vs $3.4M YoY; invested $277.1M in investing activities including $347.9M marketable securities purchases; financed with $12.6M cash from financing activities, down from $511.4M in 2024
  • Management notes macroeconomic uncertainty, higher contractual allowance reserves due to payer claim denials, expects liquidity sufficiency for 12 months, terminated Verily collaboration to focus on clinical-grade wearables

AI summary of the IRTC 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $221.6M, up 15% YoY from $192.9M, driven by higher Zio monitor and Zio AT volumes
  • Gross margin 74.2% vs 71.1% YoY, supported by $3.1M tariff refunds and manufacturing efficiencies
  • Net loss $29.9M vs $5.2M, including $49.8M litigation settlements and $6.6M transformation costs
  • Cash $394.7M, marketable securities $166.0M, operating cash flow $29.3M vs $54.7M
  • VitalConnect acquisition closed October 5 for approximately $237.5M cash, with macroeconomic pressure and payer reimbursement challenges remaining headwinds

Risk Factors

  • New acquisition risk: VitalConnect acquired October 5, 2026, creating integration challenges across regulatory, quality, clinical, and billing functions
  • Most materially updated regulatory risk: FDA QMSR effective February 2, 2026, creating uncertainty around future device-quality inspections
  • Legal and compliance risk: DOJ civil investigative demand dated December 12, 2025, seeks information on Zio AT and related reimbursement claims
  • Near-term operational risk: AI-enabled payer audits increase billing scrutiny and could delay or reduce revenue and accounts receivable
  • Financial risk: Medicare represented approximately 26% of total revenue during the three and nine months ended September 30, 2026

AI summary of the IRTC 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 17, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Press release announces iRhythm’s entry into an accelerated share repurchase agreement
  • Share repurchase details appear in Exhibit 99.1 and may affect share count and capital allocation

Item 8.01: Other Events

  • $100.0M accelerated share repurchase with JPMorgan, half of the previously authorized $200.0M program
  • Initial delivery represents approximately 80% of expected repurchased shares, with final share count tied to trading prices
Filed Nov 13, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Deferred compensation plan effective January 1, 2027, covering eligible employees, named executives, and non-employee directors
  • Executives may defer up to 80% of base salary and 100% of annual bonuses
Filed Nov 12, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • iRhythm announced a share repurchase program on November 11, 2026
  • Buybacks may signal management views the stock as undervalued

Item 8.01: Other Events

  • Board authorized up to $200.0 million for common-stock repurchases
  • Funding planned from existing cash, cash equivalents and ongoing operating cash flow

Item EX-99.1: Item EX-99.1

  • Board authorized up to $200 million in common-stock repurchases, signaling confidence in core operations and VitalConnect growth opportunities
  • Funding expected from existing cash, cash equivalents and ongoing operating cash flow, reducing flexibility for other uses

AI summaries of IRTC 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for IRTC

Don't miss the next IRTC filing

  • Alerts as it files. A push when IRTC files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut IRTC, by share count.
  • Ask anything. An AI agent that reads every IRTC filing and answers with sources.

IRTC alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
TALWALKAR ABHIJIT YBuyNov 19, 2026$96.67
Wilson Daniel G.SellSep 2, 2026$121.83
Turakhia MinangSellAug 10, 2026$124.65
Shrishrimal SumiSellAug 10, 2026$124.65
Patterson ChadSellAug 10, 2026$124.65
Blackford Quentin S.SellAug 10, 2026$124.65
Murphy Patrick MichaelSellAug 10, 2026$124.65
Shrishrimal SumiAAug 7, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$591.8M$747.1M
Gross Profit-$407.5M$527.3M
Operating Income--$115.5M-$57.4M
Net Income--$113.3M-$44.6M
Gross Margin-68.9%70.6%
Op. Margin--19.5%-7.7%
Net Margin--19.1%-6.0%
Balance Sheet
Total Assets$433.1M$931.4M$1.0B
Equity$210.1M$90.9M$152.7M
ROE--124.6%-29.2%
Per Share
EPS-$-3.63$-1.39
Cash Flow
Operating CF-$3.4M$80.9M
CapEx-$33.9M$46.3M

Source: XBRL data in iRhythm Holdings, Inc. (IRTC)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate IRTC share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
IRTC shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202628$1.29B
Q2 202629$1.63B
Q1 202631$1.63B
Q4 202529$2.23B
Q3 202530$2.06B
Q2 202529$1.69B
Q1 202524$787.0M
Q4 202420$543.6M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 220 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

IRTC filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 19, 2026--
8-KNov 17, 2026Analysis-
8-KNov 13, 2026Analysis-
8-KNov 12, 2026Analysis-
10-QNov 5, 2026Analysis
8-KNov 5, 2026Analysis-
8-KOct 5, 2026Analysis-
8-KSep 22, 2026Analysis-
4Sep 3, 2026--
SC 13GAug 13, 2026-
8-KAug 13, 2026Analysis-
4Aug 11, 2026--
4Aug 11, 2026--
4Aug 11, 2026--
4Aug 11, 2026--
4Aug 11, 2026--
8-KAug 6, 2026Analysis-
10-QAug 6, 2026Analysis
8-KAug 6, 2026Analysis-
4Aug 4, 2026--
4Aug 4, 2026--
4Aug 4, 2026--
4Jul 6, 2026--
4Jul 6, 2026--
8-KJun 15, 2026Analysis-

Related Health Care companies

All Health Care →

IRTC SEC filings: frequently asked questions

Are IRTC insiders buying or selling?

In the last 90 days, iRhythm Holdings, Inc. (IRTC) officers, directors and 10% owners reported 1 open-market purchase worth $763,706 by 1 insider and 1 open-market sale worth $94,175 by 1 insider on Form 4, a net purchase of $669,532. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold IRTC stock?

As of September 30, 2026, the largest iRhythm Holdings, Inc. (IRTC) holders among the 13F filers tracked by SignalX were BlackRock ($341.7 million), Vanguard Portfolio Management LLC ($225.2 million), Vanguard Capital Management LLC ($166.5 million), State Street Corp ($98.2 million), Invesco Ltd ($90.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was IRTC's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), iRhythm Holdings, Inc. (IRTC) reported revenue of $747.1 million (up 26.2% from FY2024) and a net loss of $44.6 million. Diluted EPS was -$1.39. The figures come from the XBRL data in the 10-K.

What are the main risks in IRTC's latest 10-K?

In the 10-K filed February 19, 2026, iRhythm Holdings, Inc. (IRTC) flagged: No geopolitical or macroeconomic threat with concrete exposure detailed. Operational risk: dependency on Nasdaq Global Select Market listing under symbol "IRTC" for liquidity and capital access. (AI summary of the Risk Factors section.)

What did IRTC report in its latest 8-K?

iRhythm Holdings, Inc. (IRTC) filed an 8-K on November 17, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events). Press release announces iRhythm’s entry into an accelerated share repurchase agreement.

What are the latest IRTC SEC filings?

iRhythm Holdings, Inc. (IRTC) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 17, 2026 and a Form 4 insider filing on November 19, 2026.

What is IRTC's SEC CIK number?

iRhythm Holdings, Inc. (IRTC)'s SEC Central Index Key (CIK) is 1388658. EDGAR lists every IRTC filing under that number.

Ask anything about IRTC

The research agent reads IRTC's filings, financials, insider trades and 13F holders, then answers with sources.